Related Experiment Videos
Cancer prevalence in Central Europe: the EUROPREVAL Study
J M Lutz1, S Francisci, E Mugno
1Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland. jean-michel.lutz@imsp.unige.ch
Summary
Cancer prevalence varies significantly across Central European nations, with higher rates in economically developed countries like Germany and Switzerland. This suggests a link between economic status, improved cancer survival, and the need for continued prevention efforts.
Area of Science:
- Oncology
- Public Health
- Epidemiology
Background:
- Cancer prevalence data is scarce for Central European countries.
- Understanding cancer burden is crucial for public health planning.
Purpose of the Study:
- To estimate and analyze cancer prevalence across seven Central European countries.
- To identify variations in cancer prevalence by country, sex, and cancer type.
Main Methods:
- Utilized cancer registry data from Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia, and Switzerland.
- Estimated prevalence for various cancers including stomach, lung, breast, and prostate, as well as all malignant neoplasms combined.
- Analyzed prevalence by time since diagnosis to assess long-term survival and cure rates.
Main Results:
- Significant heterogeneity in cancer prevalence was observed, ranging from 730 to 3350 per 100,000 population.
- Germany and Switzerland reported the highest overall prevalence, while Poland and Slovenia had the lowest.
- Breast cancer was most common in women; prostate cancer led in men in some countries, while lung cancer was prevalent in others. Long-term survival rates varied, with up to 50% of prevalent cases diagnosed over 10 years prior.
Conclusions:
- Higher cancer prevalence in Central Europe correlates with well-developed economies.
- This may reflect improved cancer treatments and survival rates.
- The findings underscore the importance of both primary prevention and continued advancements in cancer treatment.